Skip to main content

Advertisement

SpringerLink
Log in

Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Although antipsychotic treatment often causes weight gain and lipid abnormalities, quantitative analyses of tissue-specific body fat content and its distribution along with adipokines have not been reported for antipsychotic-treated patients.

Objectives

The purposes of the present study were to quantitatively assess abdominal and liver fat in patients with schizophrenia on antipsychotic treatment and age- and body mass index (BMI)-matched healthy controls and to evaluate their associations with plasma leptin and adiponectin levels.

Methods

In 13 schizophrenia patients on antipsychotic treatment and 11 age- and BMI-matched controls, we simultaneously quantified visceral and subcutaneous fat content using T1-weighted magnetic resonance imaging and liver fat content by 1H magnetic resonance spectroscopy. Associations of tissue-specific fat content with plasma levels of leptin and adiponectin were evaluated.

Results

Plasma adiponectin level (μg/mL) was not statistically different between groups (7.02 ± 2.67 vs. 7.59 ± 2.92), whereas plasma leptin level (ng/mL) trended to be higher in patients than in controls (11.82 ± 7.89 vs. 7.93 ± 5.25). The values of liver fat (%), visceral fat (L), and subcutaneous fat (L) were 9.64 ± 8.03 vs. 7.07 ± 7.35, 4.41 ± 1.64 vs. 3.31 ± 1.97, and 8.37 ± 3.34 vs. 7.16 ± 2.99 in patients vs. controls, respectively. Liver fat content was inversely correlated with adiponectin in controls (r =  − 0.87, p < 0.001) but not in patients (r =  − 0.26, p = 0.39). In both groups, visceral fat was inversely associated with adiponectin (controls : r =  − 0.66, p = 0.03; patients : r =  − 0.65, p = 0.02), while subcutaneous fat was positively correlated with leptin (controls : r = 0.90, p < 0.001; patients : r = 0.67, p = 0.01).

Conclusions

These findings suggest that antipsychotic treatment may disrupt the physiological relationship between liver fat content and adiponectin but does not essentially affect the associations of adiponectin and leptin with visceral and subcutaneous compartments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington DC

    Google Scholar 

  • Aye IL, Rosario FJ, Powell TL, Jansson T (2015) Adiponectin supplementation in pregnant mice prevents the adverse effects of maternal obesity on placental function and fetal growth. Proc Natl Acad Sci U S A 112:12858–12863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baptista T, Beaulieu S (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatr 47:742–749

    Google Scholar 

  • Bartoli F, Crocamo C, Clerici M, Carrà G (2015) Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis. Eur Neuropsychopharmacol 25:1767–1774

    Article  CAS  PubMed  Google Scholar 

  • Baum T, Cordes C, Dieckmeyer M, Ruschke S, Franz D, Hauner H, Kirschke JS, Karampinos DC (2016) MR-based assessment of body fat distribution and characteristics. Eur J Radiol 85:1512–1518

    Article  PubMed  Google Scholar 

  • Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA (2008) Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 28:132–137

    Article  CAS  PubMed  Google Scholar 

  • Bohte AE, van Werven JR, Bipat S, Stoker J (2011) The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 21:87–97

    Article  PubMed  Google Scholar 

  • Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Harrington LM, Miller KK (2011) Adiponectin is inversely associated with intramyocellular and intrahepatic lipids in obese premenopausal women. Obesity (Silver Spring) 19:911–916

    Article  CAS  Google Scholar 

  • Chan DC, Watts GF, Ng TW, Hua J, Song S, Barrett PH (2006) Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab 8:698–702

    Article  CAS  PubMed  Google Scholar 

  • de Leon J, Correa JC, Ruano G, Windemuth A, Arranz MJ, Diaz FJ (2008) Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 98:40–46

    Article  PubMed  Google Scholar 

  • Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106:15430–15435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, Kirkpatrick B (2009) Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194:434–438

    Article  PubMed  PubMed Central  Google Scholar 

  • Fernández-Real JM, Castro A, Vázquez G, Casamitjana R, López-Bermejo A, Peñarroja G, Ricart W (2004) Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 27:739–745

    Article  PubMed  Google Scholar 

  • First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview for DSM-IV axis I disorders research version (SCID-I). New York State Psychiatric Institute Biometrics Research, New York

    Google Scholar 

  • Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D’Agostino RB Sr, O’Donnell CJ (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39–48

    Article  PubMed  Google Scholar 

  • Fu Y (2014) Adiponectin signaling and metabolic syndrome. Prog Mol Biol Transl Sci 121:293–319

    Article  CAS  PubMed  Google Scholar 

  • Gil-Campos M, Cañete RR, Gil A (2004) Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 23:963–974

    Article  CAS  PubMed  Google Scholar 

  • Goncalves P, Araujo JR, Martel F (2015) Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 25:1–16

    Article  PubMed  Google Scholar 

  • Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Reginster JY, Collette J, Peuskens J, De Hert M (2008) A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 106:308–314

    Article  PubMed  Google Scholar 

  • Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM (2015) Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2:452–464

    Article  PubMed  Google Scholar 

  • Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y (2006) Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20:75–79

    Article  CAS  PubMed  Google Scholar 

  • Hwang JH, Stein DT, Barzilai N, Cui MH, Tonelli J, Kishore P, Hawkins M (2007) Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 293:E1663–E1669

    Article  CAS  PubMed  Google Scholar 

  • Jin H, Meyer JM, Mudaliar S, Jeste DV (2008) Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 100:70–85

    Article  PubMed  PubMed Central  Google Scholar 

  • Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276

    Article  CAS  PubMed  Google Scholar 

  • Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP (2009) Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology 207:119–125

    Article  CAS  PubMed  Google Scholar 

  • Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I (2011) Relationships between circulating adiponectin levels and fat distribution in obese subjects. J Atheroscler Thromb 18:592–595

    Article  CAS  PubMed  Google Scholar 

  • Koch C, Augustine RA, Steger J, Ganjam GK, Benzler J, Pracht C, Lowe C, Schwartz MW, Shepherd PR, Anderson GM, Grattan DR, Tups A (2010) Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic insulin sensitivity. J Neurosci 30:16180–16187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL, Yki-Jarvinen H, Oresic M (2010) Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity(Silver Spring) 18:937–944

    CAS  Google Scholar 

  • Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046–2049

    Article  CAS  PubMed  Google Scholar 

  • Lilja M, Rolandsson O, Norberg M, Söderberg S (2012) The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance. Metab Syndr Relat Disord 10:143–151

    Article  CAS  PubMed  Google Scholar 

  • Livingstone RS, Begovatz P, Kahl S, Nowotny B, Strassburger K, Giani G, Bunke J, Roden M, Hwang JH (2014) Initial clinical application of modified Dixon with flexible echo times: hepatic and pancreatic fat assessments in comparison with (1)H MRS. MAGMA 27:397–405

    Article  CAS  PubMed  Google Scholar 

  • Lu ML, Wang TN, Lin TY, Shao WC, Chang SH, Chou JY, Ho YF, Liao YT, Chen VC (2015 ) Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry: 47–50

  • Machann J, Thamer C, Stefan N, Schwenzer NF, Kantartzis K, Haring HU, Claussen CD, Fritsche A, Schick F (2010) Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 257:353–363

    Article  PubMed  Google Scholar 

  • Mattioli B, Straface E, Matarrese P, Quaranta MG, Giordani L, Malorni W, Viora M (2008) Leptin as an immunological adjuvant: enhanced migratory and CD8+ T cell stimulatory capacity of human dendritic cells exposed to leptin. FASEB J 22:2012–2022

    Article  CAS  PubMed  Google Scholar 

  • Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425–433

    Article  CAS  PubMed  Google Scholar 

  • Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17

    Article  PubMed  Google Scholar 

  • Morris DL, Rui L (2009) Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 297:E1247–E1259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Murashita M, Inoue T, Kusumi I, Nakagawa S, Itoh K, Tanaka T, Izumi T, Hosoda H, Kangawa K, Koyama T (2007) Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 61:54–58

    Article  CAS  PubMed  Google Scholar 

  • Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K, Koyama T (2005) Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30:106–110

    Article  CAS  PubMed  Google Scholar 

  • Myers MG, Cowley MA, Münzberg H (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70:537–556

    Article  CAS  PubMed  Google Scholar 

  • Neamat-Allah J, Johnson T, Nabers D, Hüsing A, Teucher B, Katzke V, Delorme S, Kaaks R, Kühn T (2015) Can the use of blood-based biomarkers in addition to anthropometric indices substantially improve the prediction of visceral fat volume as measured by magnetic resonance imaging? Eur J Nutr 54:701–708

    Article  CAS  PubMed  Google Scholar 

  • Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA (2012) Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308:1150–1159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, Kawamoto T, Matsumoto S, Nagaretani H, Kumada M, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Hiraoka H, Iwashima Y, Ishikawa K, Ohishi M, Katsuya T, Rakugi H, Ogihara T, Matsuzawa Y (2004) Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43:1195–1200

    Article  CAS  PubMed  Google Scholar 

  • Paredes RM, Quinones M, Marballi K, Gao X, Valdez C, Ahuja SS, Velligan D, Walss-Bass C (2014) Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. Int J Neuropsychopharmacol 17:1139–1148

    Article  CAS  PubMed  Google Scholar 

  • Richards AA, Hickman IJ, Wang AY, Jones AL, Newell F, Mowry BJ, Whitehead JP, Prins JB, Macdonald GA (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 26:232–237

    Article  CAS  PubMed  Google Scholar 

  • Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, Lunder N, Vidal-Puig A, Dieguez C, Berge RK, Lopez M, Steen VM (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15:163–179

    Article  CAS  PubMed  Google Scholar 

  • Sporn AL, Bobb AJ, Gogtay N, Stevens H, Greenstein DK, Clasen LS, Tossell JW, Nugent T, Gochman PA, Sharp WS, Mattai A, Lenane MC, Yanovski JA, Rapoport JL (2005) Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 44:925–933

    Article  PubMed  Google Scholar 

  • Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, Maerker E, Schick F, Häring HU, Stumvoll M (2003) Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 11:368–372

    Article  CAS  PubMed  Google Scholar 

  • Starrenburg FC, Bogers JP (2009) How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry 24:164–170

    Article  CAS  PubMed  Google Scholar 

  • Steiger JH (1980) Tests for comparing elements of a correlation matrix. Psychol Bull 87:245–251

    Article  Google Scholar 

  • Stubbs B, Wang AK, Vancampfort D, Miller BJ (2016) Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. Psychoneuroendocrinology 63:144–154

    Article  CAS  PubMed  Google Scholar 

  • Sugai T, Suzuki Y, Fukui N, Ono S, Watanabe J, Tsuneyama N, Someya T (2012) Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. J Clin Psychopharmacol 32:390–393

    Article  CAS  PubMed  Google Scholar 

  • Tai E, Lau TN, Ho SC, Fok AC, Tan CE (2000) Body fat distribution and cardiovascular risk in normal weight women. Associations with insulin resistance, lipids and plasma leptin. Int J Obes Relat Metab Disord 24:751–757

    Article  CAS  PubMed  Google Scholar 

  • Tanyanskiy DA, Martynikhin IA, Rotar OP, Konradi AO, Sokolian NA, Neznanov NG, Denisenko AD (2015) Association of adipokines with metabolic disorders in patients with schizophrenia: results of comparative study with mental healthy cohort. Diabetes Metab Syndr 9:163–167

    Article  PubMed  Google Scholar 

  • Thomas EL, Frost G, Taylor-Robinson SD, Bell JD (2012a) Excess body fat in obese and normal-weight subjects. Nutr Res Rev 25:150–161

    Article  PubMed  Google Scholar 

  • Thomas EL, Parkinson JR, Frost GS, Goldstone AP, Doré CJ, McCarthy JP, Collins AL, Fitzpatrick JA, Durighel G, Taylor-Robinson SD, Bell JD (2012b) The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring) 20:76–87

    Article  CAS  Google Scholar 

  • Togo T, Kojima K, Shoji M, Kase A, Uchikado H, Katsuse O, Iseki E, Kosaka K (2004) Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 19:37–40

    Article  PubMed  Google Scholar 

  • Wampers M, Hanssens L, van Winkel R, Heald A, Collette J, Peuskens J, Reginster JY, Scheen A, De Hert M (2012) Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 22:17–26

    Article  CAS  PubMed  Google Scholar 

  • Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM (2015) Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol 71:389–401

    Article  CAS  PubMed  Google Scholar 

  • Woods SC, D’Alessio DA (2008) Central control of body weight and appetite. J Clin Endocrinol Metab 93(11 Suppl 1):S37–S50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yan H, Chen JD, Zheng XY (2013) Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology 229:1–7

    Article  CAS  PubMed  Google Scholar 

  • Yang R, Barouch LA (2007) Leptin signaling and obesity: cardiovascular consequences. Circ Res 101:545–559

    Article  CAS  PubMed  Google Scholar 

  • Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58–62

    Article  PubMed  Google Scholar 

  • Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T (2003) Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37:193–220

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2015R1C1A2A01051461), and Gachon University Gil Medical Center (Grant #2013-33). For Jong-Hoon Kim, this work was partly supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (number: HI14C2750). The authors thank Prof. Jun-Young Chung for technical support with the Siemens scanner and Prof. Daniel T Stein at Albert Einstein College of Medicine (New York, USA) for fruitful discussion on the procedure of blood sampling and analyses. The authors also thank the radiographers for scanning participants.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine, Gachon University, Incheon, Republic of Korea

    Jong-Hoon Kim

  2. Neuroscience Research Institute, Gachon University, Incheon, Republic of Korea

    Jong-Hoon Kim

  3. Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine, Neuroscience Research Institute, Gachon University, 1198 Guwol-Dong, Namdong-Gu, Incheon, 405-760, Republic of Korea

    Jong-Hoon Kim

  4. Division of Molecular Medicine, Gachon University School of Medicine, Gachon University, Incheon, Republic of Korea

    Jung-Hyun Kim

  5. Department of Laboratory Medicine, Gil Medical Center, Gachon University School of Medicine, Gachon University, Incheon, Republic of Korea

    Pil-Whan Park

  6. Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen; German Center for Diabetes Research (DZD), München-Neuherberg, Germany

    Jürgen Machann

  7. Section on Experimental Radiology, Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany

    Jürgen Machann

  8. Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

    Michael Roden

  9. Department of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany

    Michael Roden

  10. German Center for Diabetes Research, München-Neuherberg, Germany

    Michael Roden

  11. Department of Diagnostic Radiology, Gil Medical Center, Gachon University School of Medicine, Gachon University, Incheon, Republic of Korea

    Sheen-Woo Lee

  12. Metabolic Imaging, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich-Heine University Düsseldorf, Auf’m Hennekamp 65, 40225, Düsseldorf, Germany

    Jong-Hee Hwang

Authors
  1. Jong-Hoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jung-Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pil-Whan Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jürgen Machann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheen-Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jong-Hee Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jong-Hoon Kim or Jong-Hee Hwang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, JH., Kim, JH., Park, PW. et al. Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study. Psychopharmacology 234, 1923–1932 (2017). https://doi.org/10.1007/s00213-017-4598-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-017-4598-5

Keywords

Search

Navigation